HADLIMA™ (adalimumab-bwwd) injection, 40 mg/0.4 mL & 40 mg/0.8 mL is now interchangeable with all high- and low-concentration presentations (autoinjector, prefilled syringe, and single-dose vial) of ...

HADLIMA™ (adalimumab-bwwd) injection, 40 mg/0.4 mL & 40 mg/0.8 mL is now interchangeable with all high- and low-concentration presentations ...

We’re witnessing a renaissance in cytokine targeting,” says Dr. Emily Rhodes, immunologist at the Stanford Institute for ...

Certain biologic therapies, such as ustekinumab, significantly effect hematological and lipid parameters in patients with psoriasis.

About 1 in 3 people with psoriasis who achieved clear skin with biologic drugs still had underlying inflammation that may ...

Most patients with psoriasis experienced clinical improvement or remission after metabolic and bariatric surgery (MBS) in a ...

Starjemza (ustekinumab-hmny) was approved by the FDA this week as a biosimilar to Stelara. 2 A pair of clinical trials ...

A new clinical review explores the complexities of treating psoriasis during pregnancy and lactation highlighting limited ...

The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and body.

“People with psoriasis that is severe enough to require pills, phototherapy, or biologics have a five-year reduction in life expectancy, the majority of which is due to excess risk of ...

Treatment with guselkumab among patients with psoriasis does not contribute to the risk for or progression of liver fibrosis.

No nail changes were noted. His grandfather has a history of psoriasis. Guttate psoriasis mainly affects the trunk and proximal extremities, but may be generalized in distribution. Lesions may ...